-- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________________________________________

FORM 8-K
____________________________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 19, 2009
____________________________

Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
___________________________

Delaware
(State or other jurisdiction of incorporation)

001-12215 16-1387862
(Commission File Number) (I.R.S. Employer Identification No.)
   
   
   
Three Giralda Farms  
Madison, NJ 07940
(Address of principal executive offices) (Zip Code)

     (973) 520-2700
(Registrant’s telephone number, including area code)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01. Regulation FD Disclosure

Pursuant to its existing share repurchase authority, on March 19, 2009, the Company repurchased 4,511,657 shares of its common stock, par value $.01 per share (“Common Stock”), from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., for an aggregate purchase price of $200,000,013.31. The purchase price for the Common Stock reflected a negotiated discount to the volume-weighted average trading price of the Common Stock in a trading period preceding the purchase.

 

Signature

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  March 19, 2009
   
   
  QUEST DIAGNOSTICS INCORPORATED
   
   
   
By:    
 /s/ William J. O’Shaughnessy, Jr.
  William J. O’Shaughnessy, Jr.
  Secretary